Effects of Cynara Scolymus L. on Glycemic Indices:A Systematic Review and Meta-Analysis of Randomized Clinical Trials Publisher Pubmed



Jalili C¹ ; Moradi S^{2, 3} ; Babaei A^{1, 4} ; Boozari B³ ; Asbaghi O⁵ ; Lazaridi AV⁸ ; Hojjati Kermani MA⁶ ; Miraghajani M^{7, 8} Show Affiliations
Source: Complementary Therapies in Medicine Published:2020

Abstract

Objectives: Cynara scolymus L. (common artichoke) and its products have been considered as potential phytotherapeutic agents for various conditions, such as cardiovascular, hepatic and gastric diseases, among others. Until now, the effects of artichoke and artichoke products administration on glycemic indices have not been sufficiently appraised. The present study evaluated the effects of artichoke and artichoke products administration on the glycemic indices. Methods: Clinical trials were identified in the Cochrane Library, PubMed, Embase and Scopus databases; to infinity until 15 March 2020. Weighted mean differences (WMD) were pooled using a random-effects model. Heterogeneity, sensitivity analysis and publication bias were reported using standard methods. Results: Pooled analysis of nine Randomized controlled trials (RCTs), demonstrated that the administration of artichoke and artichoke products led to a significant reduced fasting blood sugar (FBS) (WMD: −5.28 mg/dl, 95 % CI: −8.95, −1.61; p = 0.005). However, other glycemic indeces including fasting insulin (WMD: −0.45 μIU/dL, 95 % CI: −1.14, 0.25; p = 0.20), HOMA-IR (MD: −0.25, 95 % CI: −0.57, 0.07; p = 0.12) or Hemoglobin A1c (HbA1c) (WMD: −0.09, 95 % CI: −0.20, 0.02; p = 0.09) did not alter after the administration of artichoke and artichoke products. A subgroup analysis comparing the kind of intervention, revealed that just the supplementation of artichoke and artichoke products, in a noco-supplementation form, was efficacy for the reduction of Homeostatic model assessment of insulin resistance (HOMA-IR) (WMD: −0.52, 95 % CI: −0.85, −0.19; p = 0.002). Conclusions: The supplementation of artichoke and artichoke products can significantly reduce the FBS concentrations in humans. Moreover, these outcomes suggested that just the supplementation of artichoke and artichoke products is more effective in the reduction of HOMA-IR levels than the co-supplementation form. However, additional clinical trials with longer study periods are necessitated to obtain a robust conclusion for producing new guidelines as part of a healthy diet. © 2020 Elsevier Ltd